Replies to post #378853 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Let's take another one from the CTAD 2022 programme:

LB3 - TRAILBLAZER-ALZ 4: Topline study results directly comparing donanemab to aducanumab on amyloid lowering in early,
symptomatic Alzheimer’s disease
Stephen Salloway 1, Elly Lee 2, Michelle Papka 3, Andrew Pain 4, Ena Oru 4, Margaret B. Ferguson 4, Hong Wang 4, Michael Case 4,
Ming Lu 4, Emily C. Collins 4, Dawn Brooks 4, John Sims 4
1Department of Neurology and Department of Psychiatry, Alpert Medical School of Brown University, Providence, RI, USA; Butler Hospital -
Providence (United States), 2Irvine Clinical Research - Irvine (United States), 3The Cognitive and Research Center of New Jersey LLC - Springfield
(United States), 4Eli Lilly and Company - Indianapolis (United States)